ADIPOSE-DERIVED STEM CELLS AND PLATELET-RICH PLASMA: INPUTS FOR REGENERATIVE MEDICINE

Main Article Content

Annalucia Carbone Monica Rucci Luigi Annacontini Aurelio Portincasa Massimo Conese

Abstract

Abstract


Regenerative medicine and tissue engineering have the aim of restoring function due to tissue damage or organ failure. This goal can be achieved either by stimulating endogenous stem cells or by providing exogenous stem cells along with appropriate biomimetic scaffold and growth factors. Among the different sources and types of stem cells, particular attention has been given to adipose tissue-derived mesenchymal stromal cells (ADSCs). The use of ADSCs as source of adult stem cells offers numerous advantages: the collection technique is easier and less invasive than with bone marrow; these stem cells show a high proliferative rate in vitro and are endowed with multi-differentiative capability and tissue repair properties. On the other hand, therapies implying the use of growth factors for tissue regeneration are widely based on platelets: these anucleated cells are a rich source of growth factors and are physiologically involved in hemostasis, wound healing and tissue repair. Platelet-rich plasma (PRP) is an autologous platelet concentrate with antibacterial and anti-inflammatory properties and a vehicle and source of growth factors. Due to these properties, PRP is increasingly used for regenerative medicine purposes, especially in the field of wound healing and osteoarthritis. In this review article, we give an overview of the combined action of ADSCs and PRP in therapeutic applications for these pathological conditions.

Article Details

How to Cite
CARBONE, Annalucia et al. ADIPOSE-DERIVED STEM CELLS AND PLATELET-RICH PLASMA: INPUTS FOR REGENERATIVE MEDICINE. Medical Research Archives, [S.l.], v. 5, n. 10, oct. 2017. ISSN 2375-1924. Available at: <http://journals.ke-i.org/index.php/mra/article/view/1519>. Date accessed: 15 dec. 2017.
Keywords
adipose tissue-derived stem cells, growth factors, platelet-rich plasma, wound healing, osteoarthritis
Section
Research Articles

References

REFERENCES
[1] Shandalov Y, Egozi D, Koffler J, Dado-Rosenfeld D, Ben-Shimol D, Freiman A, et al. An engineered muscle flap for reconstruction of large soft tissue defects. Proc Natl Acad Sci U S A. 2014;111:6010-5.
[2] Patrick CW, Jr. Engineering Adipose Tissue for Regenerative and Reparative Therapies. Semin Plast Surg. 2005;19:207-15.
[3] Newell KA. Clinical transplantation tolerance. Semin Immunopathol. 2011;33:91-104.
[4] Orlando G, Soker S, Stratta RJ, Atala A. Will regenerative medicine replace transplantation? Cold Spring Harb Perspect Med. 2013;3.
[5] Jain A, Bansal R. Applications of regenerative medicine in organ transplantation. J Pharm Bioallied Sci. 2015;7:188-94.
[6] Jenkins DD, Yang GP, Lorenz HP, Longaker MT, Sylvester KG. Tissue engineering and regenerative medicine. Clin Plast Surg. 2003;30:581-8.
[7] Di Gioia S, Trapani A, Carbone A, Castellani S, Colombo C, Trapani G, et al. Cationic Polymers for Gene Delivery into Mesenchymal Stem Cells as a Novel Approach to Regenerative Medicine. In: Samal S, Dubruel P, editors. Cationic Polymers in Regenerative Medicine. London: Royal Society of Chemistry; 2014. p. 386-437.
[8] Conese M. Towards a Combined Gene and Cell Therapy for Lung Diseases: The Case of Induced Pluripotent Stem Cells. Adv Genet Eng. 2012;1:103.
[9] Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-5.
[10] Staal FJ, Baum C, Cowan C, Dzierzak E, Hacein-Bey-Abina S, Karlsson S, et al. Stem cell self-renewal: lessons from bone marrow, gut and iPS toward clinical applications. Leukemia. 2011;25:1095-102.
[11] Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science. 2000;287:1442-6.
[12] Yeo RWY, Lim SH. Embryonic Stem Cells for Therapies – Challenges and Possibilities. In: Kallos M, editor. Embryonic Stem Cells - Basic Biology to Bioengineering. Rijeka: inTech; 2011. p. 3-18.
[13] Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20:5-14.
[14] Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther. 2006;1:365-9.
[15] Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301-13.
[16] Elahi KC, Klein G, Avci-Adali M, Sievert KD, MacNeil S, Aicher WK. Human Mesenchymal Stromal Cells from Different Sources Diverge in Their Expression of Cell Surface Proteins and Display Distinct Differentiation Patterns. Stem Cells Int. 2016;2016:5646384.
[17] Watt SM, Gullo F, van der Garde M, Markeson D, Camicia R, Khoo CP, et al. The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential. Br Med Bull. 2013;108:25-53.
[18] Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499-506.
[19] English K, French A, Wood KJ. Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell. 2010;7:431-42.
[20] Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9:11-5.
[21] Dazzi F, Lopes L, Weng L. Mesenchymal stromal cells: a key player in 'innate tolerance'? Immunology. 2012;137:206-13.
[22] Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7:e2062.
[23] D'Souza N, Rossignoli F, Golinelli G, Grisendi G, Spano C, Candini O, et al. Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies. BMC Med. 2015;13:186.
[24] Lombardo E, van der Poll T, DelaRosa O, Dalemans W. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells. 2015;7:368-79.
[25] Jessop ZM, Al-Sabah A, Francis WR, Whitaker IS. Transforming healthcare through regenerative medicine. BMC Med. 2016;14:115.
[26] Casadei A, Epis R, Ferroni L, Tocco I, Gardin C, Bressan E, et al. Adipose tissue regeneration: a state of the art. J Biomed Biotechnol. 2012;2012:462543.
[27] Zuk P. Adipose-derived stem cells in tissue regeneration: A review. ISRN Stem Cells. 2013;2013 (2013):ID 713959.
[28] Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211-28.
[29] Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279-95.
[30] Gimble J, Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy. 2003;5:362-9.
[31] Kim Y, Kim H, Cho H, Bae Y, Suh K, Jung J. Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Cell Physiol Biochem. 2007;20:867-76.
[32] Kingham PJ, Kolar MK, Novikova LN, Novikov LN, Wiberg M. Stimulating the neurotrophic and angiogenic properties of human adipose-derived stem cells enhances nerve repair. Stem Cells Dev. 2014;23:741-54.
[33] Kapur SK, Katz AJ. Review of the adipose derived stem cell secretome. Biochimie. 2013;95:2222-8.
[34] Kingham PJ, Kalbermatten DF, Mahay D, Armstrong SJ, Wiberg M, Terenghi G. Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro. Exp Neurol. 2007;207:267-74.
[35] Chandra V, Swetha G, Muthyala S, Jaiswal AK, Bellare JR, Nair PD, et al. Islet-like cell aggregates generated from human adipose tissue derived stem cells ameliorate experimental diabetes in mice. PLoS One. 2011;6:e20615.
[36] Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Quinn G, et al. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology. 2007;46:219-28.
[37] Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, et al. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J Gastroenterol Hepatol. 2009;24:70-7.
[38] Ruiz JC, Ludlow JW, Sherwood S, Yu G, Wu X, Gimble JM. Differentiated human adipose-derived stem cells exhibit hepatogenic capability in vitro and in vivo. J Cell Physiol. 2010;225:429-36.
[39] Ma T, Sun J, Zhao Z, Lei W, Chen Y, Wang X, et al. A brief review: adipose-derived stem cells and their therapeutic potential in cardiovascular diseases. Stem Cell Res Ther. 2017;8:124.
[40] Dai R, Wang Z, Samanipour R, Koo KI, Kim K. Adipose-Derived Stem Cells for Tissue Engineering and Regenerative Medicine Applications. Stem Cells Int. 2016;2016:6737345.
[41] De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs. 2003;174:101-9.
[42] Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:1294-301.
[43] Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005;33:1402-16.
[44] Carbone A, Valente M, Annacontini L, Castellani S, Di Gioia S, Parisi D, et al. Adipose-derived mesenchymal stromal (stem) cells differentiate to osteoblast and chondroblast lineages upon incubation with conditioned media from dental pulp stem cell-derived osteoblasts and auricle cartilage chondrocytes. J Biol Regul Homeost Agents. 2016;30:111-22.
[45] Salibian AA, Widgerow AD, Abrouk M, Evans GR. Stem cells in plastic surgery: a review of current clinical and translational applications. Arch Plast Surg. 2013;40:666-75.
[46] Kim YJ, Jeong JH. Clinical application of adipose stem cells in plastic surgery. J Korean Med Sci. 2014;29:462-7.
[47] Toyserkani NM, Christensen ML, Sheikh SP, Sorensen JA. Adipose-Derived Stem Cells: New Treatment for Wound Healing? Ann Plast Surg. 2014.
[48] Steinberg JP, Hong SJ, Geringer MR, Galiano RD, Mustoe TA. Equivalent effects of topically-delivered adipose-derived stem cells and dermal fibroblasts in the ischemic rabbit ear model for chronic wounds. Aesthet Surg J. 2012;32:504-19.
[49] Lee SH, Lee JH, Cho KH. Effects of Human Adipose-derived Stem Cells on Cutaneous Wound Healing in Nude Mice. Ann Dermatol. 2011;23:150-5.
[50] Sun L, Huang Y, Bian Z, Petrosino J, Fan Z, Wang Y, et al. Sundew-Inspired Adhesive Hydrogels Combined with Adipose-Derived Stem Cells for Wound Healing. ACS Appl Mater Interfaces. 2016;8:2423-34.
[51] Altman AM, Matthias N, Yan Y, Song YH, Bai X, Chiu ES, et al. Dermal matrix as a carrier for in vivo delivery of human adipose-derived stem cells. Biomaterials. 2008;29:1431-42.
[52] Meruane MA, Rojas M, Marcelain K. The use of adipose tissue-derived stem cells within a dermal substitute improves skin regeneration by increasing neoangiogenesis and collagen synthesis. Plast Reconstr Surg. 2012;130:53-63.
[53] Lam MT, Nauta A, Meyer NP, Wu JC, Longaker MT. Effective delivery of stem cells using an extracellular matrix patch results in increased cell survival and proliferation and reduced scarring in skin wound healing. Tissue Eng Part A. 2013;19:738-47.
[54] Lin YC, Grahovac T, Oh SJ, Ieraci M, Rubin JP, Marra KG. Evaluation of a multi-layer adipose-derived stem cell sheet in a full-thickness wound healing model. Acta Biomater. 2013;9:5243-50.
[55] Kim Y, Lee SH, Kang BJ, Kim WH, Yun HS, Kweon OK. Comparison of Osteogenesis between Adipose-Derived Mesenchymal Stem Cells and Their Sheets on Poly-epsilon-Caprolactone/beta-Tricalcium Phosphate Composite Scaffolds in Canine Bone Defects. Stem Cells Int. 2016;2016:8414715.
[56] Gale AJ. Continuing education course #2: current understanding of hemostasis. Toxicol Pathol. 2011;39:273-80.
[57] Chu AJ. Tissue factor, blood coagulation, and beyond: an overview. Int J Inflam. 2011;2011:367284.
[58] Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci. 2008;13:3532-48.
[59] Koenen RR, Weber C. Platelet-derived chemokines in vascular remodeling and atherosclerosis. Semin Thromb Hemost. 2010;36:163-9.
[60] Ho-Tin-Noe B, Demers M, Wagner DD. How platelets safeguard vascular integrity. J Thromb Haemost. 2011;9 Suppl 1:56-65.
[61] Gawaz M, Vogel S. Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. Blood. 2013;122:2550-4.
[62] Burnouf T, Goubran HA, Chen TM, Ou KL, El-Ekiaby M, Radosevic M. Blood-derived biomaterials and platelet growth factors in regenerative medicine. Blood Rev. 2013;27:77-89.
[63] Hildner F, Albrecht C, Gabriel C, Redl H, van Griensven M. State of the art and future perspectives of articular cartilage regeneration: a focus on adipose-derived stem cells and platelet-derived products. J Tissue Eng Regen Med. 2011;5:e36-51.
[64] Bieback K, Schallmoser K, Kluter H, Strunk D. Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells. Transfus Med Hemother. 2008;35:286-94.
[65] Kakudo N, Minakata T, Mitsui T, Kushida S, Notodihardjo FZ, Kusumoto K. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. Plast Reconstr Surg. 2008;122:1352-60.
[66] Blanton MW, Hadad I, Johnstone BH, Mund JA, Rogers PI, Eppley BL, et al. Adipose stromal cells and platelet-rich plasma therapies synergistically increase revascularization during wound healing. Plast Reconstr Surg. 2009;123:56S-64S.
[67] Hadad I, Johnstone BH, Brabham JG, Blanton MW, Rogers PI, Fellers C, et al. Development of a porcine delayed wound-healing model and its use in testing a novel cell-based therapy. Int J Radiat Oncol Biol Phys. 2010;78:888-96.
[68] Yun S, Ku SK, Kwon YS. Adipose-derived mesenchymal stem cells and platelet-rich plasma synergistically ameliorate the surgical-induced osteoarthritis in Beagle dogs. J Orthop Surg Res. 2016;11:9.
[69] Hermeto LC, DeRossi R, Oliveira RJ, Pesarini JR, Antoniolli-Silva AC, Jardim PH, et al. Effects of intra-articular injection of mesenchymal stem cells associated with platelet-rich plasma in a rabbit model of osteoarthritis. Genet Mol Res. 2016;15.
[70] Cervelli V, De Angelis B, Lucarini L, Spallone D, Balzani A, Palla L, et al. Tissue regeneration in loss of substance on the lower limbs through use of platelet-rich plasma, stem cells from adipose tissue, and hyaluronic acid. Adv Skin Wound Care. 2010;23:262-72.
[71] Pak J, Chang JJ, Lee JH, Lee SH. Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints. BMC Musculoskelet Disord. 2013;14:337.
[72] Bui K, Duong T, Nguyen N, Nguyen T, Le V, Mai V, et al. Symptomatic knee osteoarthritis treatment using autologous adipose derived stem cells and platelet-rich plasma: a clinical study. Biomedical Research And Therapy. 2014;1:2-8.
[73] Bansal H, Comella K, Leon J, Verma P, Agrawal D, Koka P, et al. Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritis. J Transl Med. 2017;15:141.

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.